weight regain tirzepatide withdrawal leads to 25% in 82.5% of adults People who stop taking weight-loss

Initially approved at doses of 0.5 mg and 1.0 mg once weekly, it has subsequently received authorisation for a 2.0 mg once-weekly dose for the management of type 2 diabetes

Peak plasma concentrations occur approximately 24-48 hours post-injection, with a half-life of approximately five days allowing for steady-state concentrations after four weeks

What the SURMOUNT data shows The SURMOUNT-1 trial at the 36-week mark shows average weight loss of approximately 15 to 17 percent of body weight on the 10 mg and 15 mg doses

These medications are powerful tools for a chronic disease

A 10-day wait reduces tirzepatide to approximately 25% of peak levels

Tirzepatide has certain drug interactions